{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T23:44:23Z","timestamp":1782690263232,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Henan Provincial Department of Science and Technology's Key Scientific and Technological Project","award":["252102311041"],"award-info":[{"award-number":["252102311041"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573337"],"award-info":[{"award-number":["82573337"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273493"],"award-info":[{"award-number":["82273493"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573653"],"award-info":[{"award-number":["82573653"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Research and Development Joint Fund of Henan Province","award":["242301420014"],"award-info":[{"award-number":["242301420014"]}]},{"name":"Key Research and Development Program of Henan Province","award":["251111313300"],"award-info":[{"award-number":["251111313300"]}]},{"name":"Zhongyuan Science and Technology Innovation Top-notch Young Talents Program"},{"name":"Young and Middle-aged Discipline Leaders Project in Health of Henan Province"},{"name":"Support Plan for Scientific and Technological Innovation Talents in Colleges and Universities of Henan Province"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Radiotherapy is a cornerstone for glioblastoma multiforme (GBM), yet its efficacy is severely hampered by intrinsic radioresistance, the molecular basis of which remains elusive, and overcoming this resistance poses a persistent challenge for GBM therapeutics. This study aims to identify novel key regulators of radiosensitivity in glioblastoma (GBM), with the goal of developing potent radiosensitizers. By analyzing patient cohorts, we identified prolactin-releasing hormone receptor (PRLHR) as a differentially expressed molecule, with significantly elevated levels in glioma specimens from the long PFS group compared to the short PFS group. This discovery prompted us to investigate PRLHR\u2019s role in modulating GBM radiosensitivity and DNA repair. Using in vitro and in vivo models, we found PRLHR overexpression enhanced GBM radiosensitivity by promoting DNA damage accumulation and attenuating repair pathways. Mechanistically, PRLHR interacts with Y-box-binding protein-1 (YBX1), inhibiting its nuclear translocation to reduce nuclear YBX1 levels, thereby compromising DNA repair efficiency. We further demonstrated repressor element-1 binding transcription factor (REST) directly binds the\n                    <jats:italic>PRLHR<\/jats:italic>\n                    promoter to transcriptionally repress its expression. Notably, degradation of REST by the antagonist X5050 upregulated PRLHR, increased DNA damage, and enhanced the therapeutic efficacy of radiotherapy in preclinical models. Our findings delineate PRLHR as a critical regulator of GBM radiosensitivity and establish X5050 as a promising radiosensitizing agent, offering a novel precision strategy to overcome radioresistance.\n                  <\/jats:p>","DOI":"10.1186\/s43556-026-00503-7","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T23:02:53Z","timestamp":1782687773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prolactin-Releasing Hormone Receptor (PRLHR) enhances radiosensitivity and exacerbates DNA damage in glioblastoma post-irradiation by inhibiting Y-box-binding protein-1 (YBX1) nuclear translocation: a novel perspective on precision radiotherapy"],"prefix":"10.1186","volume":"7","author":[{"given":"Yuning","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minkai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qimeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongming","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4686-9241","authenticated-orcid":false,"given":"Zhenyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"Supplement_6","key":"503_CR1","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","volume":"26","author":"M Price","year":"2024","unstructured":"Price M, Ballard C, Benedetti J, Neff C, Cioffi G, Waite KA, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021. Neuro Oncol. 2024;26(Supplement_6):vi1\u201385. https:\/\/doi.org\/10.1093\/neuonc\/noae145.","journal-title":"Neuro Oncol"},{"issue":"8","key":"503_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231\u201351. https:\/\/doi.org\/10.1093\/neuonc\/noab106.","journal-title":"Neuro Oncol"},{"issue":"11","key":"503_CR3","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1093\/neuonc\/noaf177","volume":"27","author":"PY Wen","year":"2025","unstructured":"Wen PY, Weller M, Lee EQ, Touat M, Khasraw M, Rahman R, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2025;27(11):2751\u201388. https:\/\/doi.org\/10.1093\/neuonc\/noaf177.","journal-title":"Neuro Oncol"},{"issue":"7","key":"503_CR4","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jama.2023.0023","volume":"329","author":"LR Schaff","year":"2023","unstructured":"Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults: a review. JAMA. 2023;329(7):574\u201387. https:\/\/doi.org\/10.1001\/jama.2023.0023.","journal-title":"JAMA"},{"issue":"13","key":"503_CR5","doi-asserted-by":"publisher","first-page":"e2119132119","DOI":"10.1073\/pnas.2119132119","volume":"119","author":"T Nakano","year":"2022","unstructured":"Nakano T, Akamatsu K, Tsuda M, Tujimoto A, Hirayama R, Hiromoto T, et al. Formation of clustered DNA damage in vivo upon irradiation with ionizing radiation: visualization and analysis with atomic force microscopy. Proc Natl Acad Sci U S A. 2022;119(13):e2119132119. https:\/\/doi.org\/10.1073\/pnas.2119132119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"503_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nrc3958","volume":"15","author":"HE Barker","year":"2015","unstructured":"Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15(7):409\u201325. https:\/\/doi.org\/10.1038\/nrc3958.","journal-title":"Nat Rev Cancer"},{"key":"503_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.mrrev.2016.05.005","volume":"769","author":"H Erasimus","year":"2016","unstructured":"Erasimus H, Gobin M, Niclou S, Van Dyck E. DNA repair mechanisms and their clinical impact in glioblastoma. Mutat Res Rev Mutat Res. 2016;769:19\u201335. https:\/\/doi.org\/10.1016\/j.mrrev.2016.05.005.","journal-title":"Mutat Res Rev Mutat Res"},{"key":"503_CR8","doi-asserted-by":"publisher","first-page":"718636","DOI":"10.3389\/fonc.2021.718636","volume":"11","author":"A Carlos-Reyes","year":"2021","unstructured":"Carlos-Reyes A, Muniz-Lino MA, Romero-Garcia S, Lopez-Camarillo C, Hernandez-de la Cruz ON. Biological adaptations of tumor cells to radiation therapy. Front Oncol. 2021;11:718636. https:\/\/doi.org\/10.3389\/fonc.2021.718636.","journal-title":"Front Oncol"},{"issue":"1","key":"503_CR9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","volume":"6","author":"R Huang","year":"2021","unstructured":"Huang R, Zhou PK. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct Target Ther. 2021;6(1):254. https:\/\/doi.org\/10.1038\/s41392-021-00648-7.","journal-title":"Signal Transduct Target Ther"},{"key":"503_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/genes11010099","author":"JA Nickoloff","year":"2020","unstructured":"Nickoloff JA, Sharma N, Taylor L. Clustered DNA double-strand breaks: biological effects and relevance to cancer radiotherapy. Genes (Basel). 2020. https:\/\/doi.org\/10.3390\/genes11010099.","journal-title":"Genes (Basel)"},{"issue":"9","key":"503_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/nrc1451","volume":"4","author":"J Bernier","year":"2004","unstructured":"Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat Rev Cancer. 2004;4(9):737\u201347. https:\/\/doi.org\/10.1038\/nrc1451.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"503_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","volume":"22","author":"Y Wu","year":"2023","unstructured":"Wu Y, Song Y, Wang R, Wang T. Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer. 2023;22(1):96. https:\/\/doi.org\/10.1186\/s12943-023-01801-2.","journal-title":"Mol Cancer"},{"key":"503_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054883","author":"P Burko","year":"2023","unstructured":"Burko P, D\u2019Amico G, Miltykh I, Scalia F, Conway de Macario E, Macario AJL, et al. Molecular pathways implicated in radioresistance of glioblastoma multiforme: what is the role of extracellular vesicles? Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24054883.","journal-title":"Int J Mol Sci"},{"key":"503_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071763","author":"JK Matsui","year":"2022","unstructured":"Matsui JK, Perlow HK, Ritter AR, Upadhyay R, Raval RR, Thomas EM, et al. Small molecules and immunotherapy agents for enhancing radiotherapy in glioblastoma. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10071763.","journal-title":"Biomedicines"},{"issue":"10","key":"503_CR15","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.trecan.2022.05.005","volume":"8","author":"A Mittal","year":"2022","unstructured":"Mittal A, Nenwani M, Sarangi I, Achreja A, Lawrence TS, Nagrath D. Radiotherapy-induced metabolic hallmarks in the tumor microenvironment. Trends Cancer. 2022;8(10):855\u201369. https:\/\/doi.org\/10.1016\/j.trecan.2022.05.005.","journal-title":"Trends Cancer"},{"key":"503_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11010028","author":"K Ohshima","year":"2021","unstructured":"Ohshima K, Morii E. Metabolic reprogramming of cancer cells during tumor progression and metastasis. Metabolites. 2021. https:\/\/doi.org\/10.3390\/metabo11010028.","journal-title":"Metabolites"},{"issue":"4","key":"503_CR17","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1158\/1541-7786.MCR-16-0366","volume":"15","author":"Y Chen","year":"2017","unstructured":"Chen Y, Li Z, Dong Z, Beebe J, Yang K, Fu L, et al. 14-3-3\u03c3 contributes to radioresistance by regulating DNA repair and cell cycle via PARP1 and CHK2. Mol Cancer Res. 2017;15(4):418\u201328. https:\/\/doi.org\/10.1158\/1541-7786.MCR-16-0366.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"503_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/neuonc\/now136","volume":"19","author":"N Goffart","year":"2017","unstructured":"Goffart N, Lombard A, Lallemand F, Kroonen J, Nassen J, Di Valentin E, et al. CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone. Neuro Oncol. 2017;19(1):66\u201377. https:\/\/doi.org\/10.1093\/neuonc\/now136.","journal-title":"Neuro Oncol"},{"issue":"4","key":"503_CR19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3390\/metabo5040571","volume":"5","author":"M Rahman","year":"2015","unstructured":"Rahman M, Hasan MR. Cancer metabolism and drug resistance. Metabolites. 2015;5(4):571\u2013600. https:\/\/doi.org\/10.3390\/metabo5040571.","journal-title":"Metabolites"},{"issue":"6","key":"503_CR20","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1073\/pnas.1215759110","volume":"110","author":"BV Varghese","year":"2013","unstructured":"Varghese BV, Koohestani F, McWilliams M, Colvin A, Gunewardena S, Kinsey WH, et al. Loss of the repressor REST in uterine fibroids promotes aberrant G protein-coupled receptor 10 expression and activates mammalian target of rapamycin pathway. Proc Natl Acad Sci U S A. 2013;110(6):2187\u201392. https:\/\/doi.org\/10.1073\/pnas.1215759110.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"503_CR21","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/s41467-023-36966-3","volume":"14","author":"F Talbot","year":"2023","unstructured":"Talbot F, Feetham CH, Mokrosinski J, Lawler K, Keogh JM, Henning E, et al. A rare human variant that disrupts GPR10 signalling causes weight gain in mice. Nat Commun. 2023;14(1):1450. https:\/\/doi.org\/10.1038\/s41467-023-36966-3.","journal-title":"Nat Commun"},{"key":"503_CR22","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3389\/fonc.2020.01409","volume":"10","author":"W Yin","year":"2020","unstructured":"Yin W, Jiang X, Tan J, Xin Z, Zhou Q, Zhan C, et al. Development and validation of a tumor mutation burden-related immune prognostic model for lower-grade glioma. Front Oncol. 2020;10:1409. https:\/\/doi.org\/10.3389\/fonc.2020.01409.","journal-title":"Front Oncol"},{"key":"503_CR23","doi-asserted-by":"publisher","first-page":"620190","DOI":"10.3389\/fonc.2022.620190","volume":"12","author":"Y Liu","year":"2022","unstructured":"Liu Y, Xiang J, Peng G, Shen C. PRLHR immune genes associated with tumor mutation burden can be used as prognostic markers in patients with gliomas. Front Oncol. 2022;12:620190. https:\/\/doi.org\/10.3389\/fonc.2022.620190.","journal-title":"Front Oncol"},{"key":"503_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ph18030431","author":"D Geczi","year":"2025","unstructured":"Geczi D, Klekner A, Balogh I, Penyige A, Szilagyi M, Virga J, et al. Identification of deregulated miRNAs and mRNAs involved in tumorigenesis and detection of glioblastoma patients applying next-generation RNA sequencing. Pharmaceuticals (Basel). 2025. https:\/\/doi.org\/10.3390\/ph18030431.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"503_CR25","doi-asserted-by":"publisher","first-page":"e0260864","DOI":"10.1371\/journal.pone.0260864","volume":"16","author":"Q Wu","year":"2021","unstructured":"Wu Q, Yin X, Zhao W, Xu W, Chen L. Downregulation of SFRP2 facilitates cancer stemness and radioresistance of glioma cells via activating Wnt\/beta-catenin signaling. PLoS One. 2021;16(12):e0260864. https:\/\/doi.org\/10.1371\/journal.pone.0260864.","journal-title":"PLoS One"},{"issue":"6","key":"503_CR26","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.3892\/mmr.2020.11542","volume":"22","author":"T Tang","year":"2020","unstructured":"Tang T, Wang LX, Yang ML, Zhang RM. lncRNA TPTEP1 inhibits stemness and radioresistance of glioma through miR-106a-5p-mediated P38 MAPK signaling. Mol Med Rep. 2020;22(6):4857\u201367. https:\/\/doi.org\/10.3892\/mmr.2020.11542.","journal-title":"Mol Med Rep"},{"issue":"1","key":"503_CR27","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1186\/s12885-022-09791-y","volume":"22","author":"X Wu","year":"2022","unstructured":"Wu X, Li C, Wang Z, Zhang Y, Liu S, Chen S, et al. A bioinformatic analysis study of m(7)G regulator-mediated methylation modification patterns and tumor microenvironment infiltration in glioblastoma. BMC Cancer. 2022;22(1):729. https:\/\/doi.org\/10.1186\/s12885-022-09791-y.","journal-title":"BMC Cancer"},{"key":"503_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084157","author":"CH Lu","year":"2022","unstructured":"Lu CH, Wei ST, Liu JJ, Chang YJ, Lin YF, Yu CS, et al. Recognition of a novel gene signature for human glioblastoma. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23084157.","journal-title":"Int J Mol Sci"},{"key":"503_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.bcp.2018.11.005","volume":"159","author":"UD Orlando","year":"2019","unstructured":"Orlando UD, Castillo AF, Medrano MAR, Solano AR, Maloberti PM, Podesta EJ. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression. Biochem Pharmacol. 2019;159:52\u201363. https:\/\/doi.org\/10.1016\/j.bcp.2018.11.005.","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"503_CR30","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1158\/1535-7163.MCT-12-0227","volume":"11","author":"L Brizuela","year":"2012","unstructured":"Brizuela L, Ader I, Mazerolles C, Bocquet M, Malavaud B, Cuvillier O. First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer. Mol Cancer Ther. 2012;11(9):1841\u201351. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-0227.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"503_CR31","doi-asserted-by":"publisher","first-page":"e0289535","DOI":"10.1371\/journal.pone.0289535","volume":"18","author":"T Cheraghi-Shavi","year":"2023","unstructured":"Cheraghi-Shavi T, Jalal R, Minuchehr Z. TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: a systems biology approach. PLoS One. 2023;18(8):e0289535. https:\/\/doi.org\/10.1371\/journal.pone.0289535.","journal-title":"PLoS One"},{"issue":"1","key":"503_CR32","doi-asserted-by":"publisher","first-page":"12682","DOI":"10.1038\/s41598-020-69676-7","volume":"10","author":"K Zhou","year":"2020","unstructured":"Zhou K, Liu Y, Zhao Z, Wang Y, Huang L, Chai R, et al. ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity. Sci Rep. 2020;10(1):12682. https:\/\/doi.org\/10.1038\/s41598-020-69676-7.","journal-title":"Sci Rep"},{"issue":"6","key":"503_CR33","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/febs.14769","volume":"286","author":"AR Ramos","year":"2019","unstructured":"Ramos AR, Ghosh S, Dedobbeleer M, Robe PA, Rogister B, Erneux C. Lipid phosphatases SKIP and SHIP2 regulate fibronectin-dependent cell migration in glioblastoma. FEBS J. 2019;286(6):1120\u201335. https:\/\/doi.org\/10.1111\/febs.14769.","journal-title":"FEBS J"},{"key":"503_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1146\/annurev.biochem.73.011303.073723","volume":"73","author":"A Sancar","year":"2004","unstructured":"Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39\u201385. https:\/\/doi.org\/10.1146\/annurev.biochem.73.011303.073723.","journal-title":"Annu Rev Biochem"},{"issue":"9","key":"503_CR35","doi-asserted-by":"publisher","first-page":"e56230","DOI":"10.15252\/embr.202256230","volume":"24","author":"X Sun","year":"2023","unstructured":"Sun X, Gao C, Xu X, Li M, Zhao X, Wang Y, et al. FBL promotes cancer cell resistance to DNA damage and BRCA1 transcription via YBX1. EMBO Rep. 2023;24(9):e56230. https:\/\/doi.org\/10.15252\/embr.202256230.","journal-title":"EMBO Rep"},{"issue":"9","key":"503_CR36","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/stem.1430","volume":"31","author":"J Charbord","year":"2013","unstructured":"Charbord J, Poydenot P, Bonnefond C, Feyeux M, Casagrande F, Brinon B, et al. High throughput screening for inhibitors of REST in neural derivatives of human embryonic stem cells reveals a chemical compound that promotes expression of neuronal genes. Stem Cells. 2013;31(9):1816\u201328. https:\/\/doi.org\/10.1002\/stem.1430.","journal-title":"Stem Cells"},{"issue":"1","key":"503_CR37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41594-024-01391-7","volume":"32","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Chen K, Tang SC, Cai Y, Nambu A, See YX, et al. Super-silencer perturbation by EZH2 and REST inhibition leads to large loss of chromatin interactions and reduction in cancer growth. Nat Struct Mol Biol. 2025;32(1):137\u201349. https:\/\/doi.org\/10.1038\/s41594-024-01391-7.","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"503_CR38","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1200\/JCO.2016.70.7562","volume":"35","author":"EP Sulman","year":"2017","unstructured":"Sulman EP, Ismaila N, Armstrong TS, Tsien C, Batchelor TT, Cloughesy T, et al. Radiation therapy for glioblastoma: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology guideline. J Clin Oncol. 2017;35(3):361\u20139. https:\/\/doi.org\/10.1200\/JCO.2016.70.7562.","journal-title":"J Clin Oncol"},{"issue":"1","key":"503_CR39","doi-asserted-by":"publisher","first-page":"19578","DOI":"10.1038\/s41598-019-55860-x","volume":"9","author":"AS Asad","year":"2019","unstructured":"Asad AS, Candia AJN, Gonzalez N, Zuccato CF, Abt A, Orrillo SJ, et al. Prolactin and its receptor as therapeutic targets in glioblastoma multiforme. Sci Rep. 2019;9(1):19578. https:\/\/doi.org\/10.1038\/s41598-019-55860-x.","journal-title":"Sci Rep"},{"issue":"1","key":"503_CR40","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","volume":"5","author":"RX Huang","year":"2020","unstructured":"Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020;5(1):60. https:\/\/doi.org\/10.1038\/s41392-020-0150-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"503_CR41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/ars.2013.5668","volume":"21","author":"WL Santivasi","year":"2014","unstructured":"Santivasi WL, Xia F. Ionizing radiation-induced DNA damage, response, and repair. Antioxid Redox Signal. 2014;21(2):251\u20139. https:\/\/doi.org\/10.1089\/ars.2013.5668.","journal-title":"Antioxid Redox Signal"},{"issue":"1107","key":"503_CR42","doi-asserted-by":"publisher","first-page":"20190494","DOI":"10.1259\/bjr.20190494","volume":"93","author":"S Deycmar","year":"2020","unstructured":"Deycmar S, Faccin E, Kazimova T, Knobel PA, Telarovic I, Tschanz F, et al. The relative biological effectiveness of proton irradiation in dependence of DNA damage repair. Br J Radiol. 2020;93(1107):20190494. https:\/\/doi.org\/10.1259\/bjr.20190494.","journal-title":"Br J Radiol"},{"issue":"1","key":"503_CR43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ccell.2017.05.011","volume":"32","author":"M Marchesini","year":"2017","unstructured":"Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D\u2019Anca M, et al. ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma. Cancer Cell. 2017;32(1):88-100 e6. https:\/\/doi.org\/10.1016\/j.ccell.2017.05.011.","journal-title":"Cancer Cell"},{"issue":"13","key":"503_CR44","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1134\/S0006297911130049","volume":"76","author":"IA Eliseeva","year":"2011","unstructured":"Eliseeva IA, Kim ER, Guryanov SG, Ovchinnikov LP, Lyabin DN. Y-box-binding protein 1 (YB-1) and its functions. Biochemistry (Mosc). 2011;76(13):1402\u201333. https:\/\/doi.org\/10.1134\/S0006297911130049.","journal-title":"Biochemistry (Mosc)"},{"issue":"5","key":"503_CR45","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1111\/cas.14006","volume":"110","author":"M Kuwano","year":"2019","unstructured":"Kuwano M, Shibata T, Watari K, Ono M. Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. Cancer Sci. 2019;110(5):1536\u201343. https:\/\/doi.org\/10.1111\/cas.14006.","journal-title":"Cancer Sci"},{"issue":"4","key":"503_CR46","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1349-7006.2004.tb03214.x","volume":"95","author":"K Shibahara","year":"2004","unstructured":"Shibahara K, Uchiumi T, Fukuda T, Kura S, Tominaga Y, Maehara Y, et al. Targeted disruption of one allele of the Y-box binding protein-1 (YB-1) gene in mouse embryonic stem cells and increased sensitivity to cisplatin and mitomycin C. Cancer Sci. 2004;95(4):348\u201353. https:\/\/doi.org\/10.1111\/j.1349-7006.2004.tb03214.x.","journal-title":"Cancer Sci"},{"issue":"3","key":"503_CR47","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/s0014-5793(97)01296-9","volume":"417","author":"K Koike","year":"1997","unstructured":"Koike K, Uchiumi T, Ohga T, Toh S, Wada M, Kohno K, et al. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett. 1997;417(3):390\u20134. https:\/\/doi.org\/10.1016\/s0014-5793(97)01296-9.","journal-title":"FEBS Lett"},{"issue":"1","key":"503_CR48","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s12035-015-9658-4","volume":"54","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Zhu M, Yu Y, Qiu L, Zhang Y, He L, et al. Brain REST\/NRSF is not only a silent repressor but also an active protector. Mol Neurobiol. 2017;54(1):541\u201350. https:\/\/doi.org\/10.1007\/s12035-015-9658-4.","journal-title":"Mol Neurobiol"},{"issue":"3","key":"503_CR49","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1158\/1535-7163.MCT-04-0228","volume":"4","author":"GN Fuller","year":"2005","unstructured":"Fuller GN, Su X, Price RE, Cohen ZR, Lang FF, Sawaya R, et al. Many human medulloblastoma tumors overexpress repressor element-1 silencing transcription (REST)\/neuron-restrictive silencer factor, which can be functionally countered by REST-VP16. Mol Cancer Ther. 2005;4(3):343\u20139. https:\/\/doi.org\/10.1158\/1535-7163.MCT-04-0228.","journal-title":"Mol Cancer Ther"},{"issue":"38","key":"503_CR50","doi-asserted-by":"publisher","first-page":"16685","DOI":"10.1073\/pnas.0906917107","volume":"107","author":"JJ Abrajano","year":"2010","unstructured":"Abrajano JJ, Qureshi IA, Gokhan S, Molero AE, Zheng D, Bergman A, et al. Corepressor for element-1-silencing transcription factor preferentially mediates gene networks underlying neural stem cell fate decisions. Proc Natl Acad Sci U S A. 2010;107(38):16685\u201390. https:\/\/doi.org\/10.1073\/pnas.0906917107.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"503_CR51","doi-asserted-by":"publisher","first-page":"R665","DOI":"10.1016\/j.cub.2005.08.032","volume":"15","author":"JM Coulson","year":"2005","unstructured":"Coulson JM. Transcriptional regulation: cancer, neurons and the REST. Curr Biol. 2005;15(17):R665\u20138. https:\/\/doi.org\/10.1016\/j.cub.2005.08.032.","journal-title":"Curr Biol"},{"key":"503_CR52","doi-asserted-by":"publisher","first-page":"834620","DOI":"10.3389\/fcell.2022.834620","volume":"10","author":"XJ Su","year":"2022","unstructured":"Su XJ, Shen BD, Wang K, Song QX, Yang X, Wu DS, et al. Roles of the neuron-restrictive silencer factor in the pathophysiological process of the central nervous system. Front Cell Dev Biol. 2022;10:834620. https:\/\/doi.org\/10.3389\/fcell.2022.834620.","journal-title":"Front Cell Dev Biol"},{"key":"503_CR53","doi-asserted-by":"publisher","first-page":"52017","DOI":"10.3791\/52017","volume":"91","author":"AM Pierce","year":"2014","unstructured":"Pierce AM, Keating AK. Creating anatomically accurate and reproducible intracranial xenografts of human brain tumors. J Vis Exp. 2014;91:52017. https:\/\/doi.org\/10.3791\/52017.","journal-title":"J Vis Exp"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00503-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00503-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00503-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T23:02:55Z","timestamp":1782687775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00503-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00503-7","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Zhengzhou University (Approval No. 2019-KY-0032). Informed consent was obtained from all individual participants included in the study. Additionally, all procedures involving animal models were performed in compliance with ethical standards and were approved by the institutional ethics committee of Zhengzhou University (Approval No. ZZU-LAC20231201).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}